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1n~Qdu~U~n
Genetic engineering technology has recently generated techniques for mak-
ing specic and precise alterations to the genetic composition of crops grown
as food for humans and animals. These advances should facilitate the devel-
opment of crops with enhanced resistance to diseases, pests and bad weather,
improved tolerance of environmentally safer herbicides, and greater nutritional
value. However, the very power of these techniques has raised fears of potential
ecological catastrophe, as well as religious and aesthetic questions that arise
from the prospect of vegetables containing genes ultimately derived from sh
and animals. This essay briey reviews the nature of the technology and its
potential benets and risks. It then discusses the regulatory framework with
particular emphasis on the regulatory strategy adopted by FDA. Finally, it
suggests that FDA's stance, while legally and scientically defensible, is strate-
gically misconceived in that stricter regulation would promote public acceptance
of this technology.
Nature of the technology
Mankind has been manipulating food crops for millennia. All modem sta-
ple crops are derived from originally wild varieties domesticated by man and
propagated far beyond their natural ecological niches. Human intervention was
limited at rst to articial selection of variants occurring through natural mu-
tation and gene rearrangement. The discovery of Mendelian genetics in the last
century made possible rationally directed breeding programs. Though scientic
principles now informed the selection of hybrids and generation of true-breeding
strains, traditional breeding still depended on naturally occurring variations;
hybrids could be generated only by
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1crossing variants of the same species. Nevertheless, traditional breeding tech-
niques have resulted in dramatic changes in foods: for instance, a small berry
native to Asia (chinese gooseberry) was transformed into the large kiwifruit now
popular in America and Europe.1
Biotechnology has been applied to food crops in two successive waves. Old
biotechnology employs articial techniques to increase variation in target plants
(so as to enhance the likelihood of nding a desirable trait) and to facilitate
transfer of genes across the species barrier. Thus, random mutations are in-
duced by treatment with chemicals or irradiation (mutagenesis) or facilitated
by cloning cells from cultures of callus or leaf (somaclonal variation). Fertile
progeny can be derived from wide crosses (between dierent species) by tech-
niques such as embryo rescue and chromosomal doubling 2
New biotechnology uses genetic engineering techniques to select genes encod-
ing desirable traits and introduce them into cells of host plants in which these
traits are desired. By culturing whole plants from these altered cells, transgenic
plant lines can be produced that contain the inserted gene in every cell and
transmit the inserted gene to every successive generation. These genetic engi-
neering techniques represent a powerful advance in two respects. First, it is now
possible to select and insert a desirable gene without simultaneously introduc-
ing other, undesirable traits that must later be eliminated through traditional
breeding (or tolerated). Second, the species barrier is eradicated. Plants can
receive genes from viruses, bacteria, other plants or animals (including man).
The inserted genetic material is laboratory-made and consists of the gene
encoding the desired trait together with additional genetic material to achieve
permanent incorporation into cells of the host plant and ecient expression of
the desired trait. Currently, these workhorse genes are derived from bacteria
that naturally infect plants { a fact that has regulatory consequences. In
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mit selection of those few altered cells that receive functioning inserted genetic
material for further study. After this initial selection, the marker gene plays no
useful role, but nevertheless continues functioning in every cell of every plant in
every subsequent generation. Since the marker currently used is an antibiotic-
resistance gene derived from a bacterium that commonly causes disease in hu-
mans, this aspect of the technique presents a regulatory issue.
Potential benets of the technology
Genetic engineering techniques vastly expand the repertoire of alterations
that are feasible in food crops. By 1992, over 30 transgenic crops were being
eld tested.3 The front runner, the Flavr Savr tomato developed by Calgene,
illustrates the commercial potential of even elementary modications. In order
to slow down the process of ripening and softening that eventually renders toma-
toes unt for sale, Calgene isolated the gene encoding an enzyme responsible
for this process (polygalacturonase, PG) and inserted it backwards (antisense).
When the normal gene becomes active during ripening and produces the chem-
ical message (mRNA) that would normally cause the cells to make the PG
enzyme, this message complexes with the product of the antisense gene and is
rapidly destroyed. Since the cells are unable to make PG, softening is greatly
retarded, and spoilage of the vine-ripened tomatoes correspondingly reduced.
The rmer texture of these tomatoes is also valued in processing. In several
ways, this is an ideal test product. The desired trait depends not on introduc-
ing a protein derived from other plants or from animals, but on preventing the
appearance of a tomato protein. Calgene has subjected its product to exten-
sive testing, including full characterization of the inserted genetic construct to
prove its stability and extensive toxicological analysis on the individual tomato
variants developed.
Other proposed applications are even more ambitious and oer tantalizing
prospects for
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developing world.4 Crops can be made resistant to insect pests, e.g. by intro-
ducing genes encoding a selectively toxic bacterial protein (the Bt protein) that
does not aect mammals, sh, plants or benecial insects. Resistance could be
conferred against plant viruses and against adverse weather conditions such as
frost and changes in temperature. There are proposals to develop salt-tolerant
crops that could be grown in arid regions upon irrigation with pure or partly
desalinized sea-water. Altered feed crops are being developed with increased
amounts of essential amino acids such as lysine and methionine. Similar modi-
cations to staple crops could do much to alleviate protein malnutrition in the
developing world. Foods being modied to combat diseases of industrialized
nations include strawberries rich in the cancer-protective agent ellagic acid, and
rapeseed enriched in unsaturated fats as a source of healthier canola oil. Crops
that can x nitrogen (or that harbor nitrogen-xing bacteria, as legumes do)
would decrease the need for articial fertilizers, beneting the ecology of in-
dustrialized nations and the food supply of developing ones. Crops that resist
broad-spectrum herbicides will permit the use of environmentally friendly herbi-
cides chosen for their rapid disappearance from the soil rather than their narrow
killing spectrum.
Contrary to the claims of some critics, the economics of genetic engineering
suggest benets for the developing world. The nature of the technology requires
great sophistication to produce transgenic plants but not to exploit them. Crops
could be custom-made in western laboratories and the seeds distributed directly
to farmers in the developing world, making this a highly sophisticated yet fully
appropriate technology. Presumably western donor governments would be dis-
posed to fund aid projects that directly benetted not merely their domestic
economies but also the biotechnology sector they have targeted for promotion.
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(I) Risks arising from cultivation
Genetic material in transgenic crops is transmitted to successive generations
of the transgenic crop itself and has the potential to spread through cross-
pollination to native (non-transgenic) variants of the same species (whether
cultivated or wild) and to other sexually compatible species.3 Contamination
of native seeds with seeds from transgenic variants will produce mixed crops in
the next generation; it is likely that native and transgenic seeds and plants will
be indistinguishable to the native eye. In this way, transgenic crops could enter
the food supply unrecognized, frustrating attempts to track and label them.
Inserted genetic material could also be acquired by bacteria or viruses that
infect the transgenic plants (horizontal transfer); these micro-organisms could
conceivably act as vectors to convey the genetic constructs to other plants.
Though theoretically valid, these events are probably very infrequent; moreover,
the same potential exists for genes native to the plant. The one exception to this
complacent assessment is the antibiotic resistance gene inserted as a marker for
the genetically altered cells. This gene is derived from bacteria, which transfer
antibiotic resistance genes amongst one another. Antibiotic resistance would
confer a selective advantage on bacteria in settings where use of that antibiotic
is widespread. USDA has accepted calculations, based on a worst case scenario,
that even if such transfers occur the antibiotic-resistant soil bacteria that result
would represent 1.4 x 10 of the resistant microbes already present.6
Genetic manipulation of plants may confer a competitive advantage and
create the potential for growth as a weed. This is likeliest with alterations that
confer resistance to pests or chemicals or reduce the need for fertilizers, and is
a major consideration in USDA regulatory policy.
(2) Risks arising from use as food or food components
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nutritional value of food, introduce proteins capable of provoking allergic re-
sponses, or reduce the eectiveness of certain antibiotics.
Many plants contain toxic substances. Most edible plants, when ripe, have
low enough levels of poisons to permit safe ingestion; in some (such as cassava
and some legumes) proper preparation is required before the food can be safely
eaten. Genetic manipulation could introduce toxic substances or increase their
concentration by a variety of mechanisms. Interfering with the normal ripening
process could prevent the normal decrease in toxic substances that accompanies
ripening. For instance, tomatoes belong to the same plant family as the Deadly
Nightshade; the Flavr Savr tomato was specically tested for tomatine and other
potentially poisonous glykoalkaloids in ripe and green fruit, for each line to be
commercialized.7 Introduced substances that are innocuous in the donor plant
could be metabolized dierently by the host, with toxic results. The introduced
genetic material, which by current techniques is inserted at a random site in
the host's genes, may by chance inactivate a metabolic pathway required to
neutralize a toxic intermediate or may reactivate a toxic pathway silenced during
evolution.
By similar mechanisms, genetic manipulation may reduce the nutritional
value of food either by altering the level or bioavailability of important nutri-
ents or by altering the chemical nature of important nutrients. If this technology
had arisen before we realized the importance of saturated fats in contributing
to heart disease and certain cancers, it is unlikely that transgenic plants would
have been monitored for alterations in these components; one can only specu-
late about other aspects of nutrition that we currently fail to monitor through
ignorance.
Food allergy is well recognized, but imperfectly understood. It is highly
idiosyncratic. The propensity for allergic reactions runs in families, but the
provoking allergens dier for each
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counselled to avoid foods known to be allergenic to them. Some foods (e.g.
shellsh, nuts) commonly provoke allergic reactions. In some cases the provoking
allergen { generally a protein { is known (e.g. gluten in wheat), but in most
cases it is not. While tests with allergic volunteers can identify major allergenic
components, the idiosyncratic nature of allergy dictates that a food can never
be pronounced free of introduced allergens for an particular allergic individual.
Allergic consumers always eat any new food at the risk of provoking a reaction;
only a warning that the food has been genetically engineered (and disclosing
the origin of any protein introduced) can trigger the appropriate precautions.
Potential interference with antibiotics has become a heated topic. Currently
technology requires the introduction of an antibiotic resistance gene as a marker
for transfected cells. The 30 products closest to market use the kad gene (which
encodes the enzyme kanamycin phosphotransferase II and confers resistance to
medically important antibiotics such as kanamycin and neomycin). Both the
kanr gene and its enzyme product will be present in food derived from the
transgemc plants, raising the possibility that the enzyme may interfere with
orally administered kanamycin or neomycin, and that the gene may be trans-
ferred to gut bacteria and make them resistant. FDA appears to accept that the
enzyme represents little danger, since it will be digested like any other protein
and even while intact would not be able to act in the chemical environment of
the gut. Moreover, these antibiotics are poorly absorbed and are rarely given
orally.' FDA responded less convincingly to the issue raised by the gene when it
pointed to widespread topical use of neomycin-containing ointments as a major
factor in inducing resistance. The agency has not explained why these ointments
should not be restricted from OTC use rather than used as the predicate for
promoting yet more resistance to an important group of antibiotics, commonly
used
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(3) Religious, aesthetic and ecological concerns
Transferring genes across species raises religious and aesthetic concerns.
Consumers who avoid certain species on religious grounds (pigs for Muslims,
cows for Hindus, various species of animals, sh and crustaceans for Jews) or for
moral or aesthetic reasons (vegetarians, vegans) must confront the issues raises
by genetically engineered plants that express genes originally derived from an-
imal species. Most people might feel qualms about eating plants whose genes
were partly human. FDA has taken the position that scientists do not infuse
the plant with the original genes that were removed from the animal and that
there is no scientic evidence that such genetic alterations change the essential
nature of the plant or confer animal-like characteristics.9 The agency therefore
concludes that information on the label disclosing the use of genetic engineer-
ing and indicating the transgene's origin would not be material, no matter how
earnestly consumers desire it. This is a callous and glib response to issues that
are religious and aesthetic rather than scientic and on which FDA manifestly
lacks expertise.
Critics have raised concerns about the economic impact of high technology
crops that would benet large agricultural producers over small farmers, and
industrialized nations over third world agricultural exporters. Commentators
have pointed to secondary ecological eects such as promoting increased use of
toxic chemicals'0 and reducing ecological diversity.
Regulatory strategy of USDA
Regulation by USDA is aimed at protecting agriculture from harmful ef-
fects of genetically engineered crops, concerns distinct from their regulation as
food. However, comparison of the regulatory strategy of USDA and FDA re-
veals distinctly dierent approaches by two agencies both eager to promote this
technology and reluctant to burden it with unnecessary regulation. Despite
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that adopted the more active monitoring role. Paradoxically, it appears that
closer regulation along the USDA model may promote rather than retard this
new industry.
USDA has asserted jurisdiction over transgenic crops under the Federal Plant
Pest Act, 7 U.S.C. xlSOaa-lSOjj and the Plant Quarantine Act, 7 U.S.C. xx151-
164a, 166~l67I2. This jurisdiction is based primarily on the presence of inserted
genetic material derived originally from bacteria or viruses that infect plants.
In general, prior approval (by obtaining a permit) is needed before a genetically
engineered plant can be introduced into agriculture, whether for eld testing
or commercial farming. However, certain host species have been designated as
having negligible risk for inadvertent transfer of inserted genes to other crops.
Genetically engineered variants of these species (corn, cotton, potato, soybean,
tobacco, tomato) can be introduced without prior approval provided USDA is
notied in the prescribed form. Moreover, an interested party can petition for
deregulation of a particular genetically engineered plant. Calgene successfully
petitioned for deregulation of its Flavr Savr tomato under this procedure.'3
USDA has adopted a exible regulatory strategy that avoids blanket deter-
minations early in the history of an emerging new technology. For most crops,
the agency requires premarket approval. For some species with lower risk, the
agency is willing to play a monitoring role. Where the accumulated data justies
it, the agency will grant deregulated status.
Regulatory strategy of FDA
FDA's regulatory strategy is founded on a science-based approach and on the
premise that genetic engineering is simply an extension of traditional breeding
and of old biotechnology by application of new techniques. By regulating the
products of genetic engineering and declining to regulate the process, FDA seeks
to incorporate genetic engineering into its existing regulatory
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FDA relies primarily on x 402(a)(l) of the Food, Drug, And Cosmetic Act
(EDGA) to regulate food from genetically engineered plants. Any constituent of
these foods that is newly introduced or expressed at higher levels following the
manipulation is regarded as an added substance within the meaning of this sec-
tion and thus regulated under the strict may render injurious to health standard.
Food is adulterated if there is a reasonable possibility that its consumption will
be injurious to health.'5 This standard applies whether the alteration is inten-
tional or inadvertent, and the producer bears legal responsibility for meeting it.
FDA's policy is to guide the industry by formal guidelines and informal con-
sultation, while reserving its formidable civil and criminal enforcement powers
until breaches have occurred.'6 The agency thus intends to play a consultative
and policing rather than a licensing role.
Any substance intended as a food component, unless generally regarded as
safe (GRAS), is subject to regulation under xx 201(s) & 409 as a food additive.
Food additives are banned unless exempted by regulation { i.e. they are subject
to licensing by FDA. The agency's reluctance to play an extensive licensing role
is evident in its published guidelines.
First, FDA adopts a narrow interpretation of the intended use test of x
201(s). The statutory language covers any substance the intended use of which
results or may reasonably be expected to result, directly or indirectly, in its
becoming a component or otherwise aecting the characteristics of any food...
Despite this very broad language, FDA treats as potential food additives only
the transferred genetic material and the in1~nd~l expression product.'7 Second,
FDA has adopted a broad view of GRAS. It states categorically that [i]ntroduced
nucleic acids [i.e. foreign genetic material, in and of themselves, do not raise
safety concerns. and are presumed GRAS.'8 This is surprising in view of the
concern that antibiotic resistance genes
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resistance. The agency will presume as GRAS any introduced substance that
is present in currently consumed foods at generally comparable or greater lev-
els. However, any signicant modication in structure, function or composition
from substances found currently in food would raise a GRAS issue. Modica-
tions are thus tested against substances found ~wx~nUyiaf~l and not substances
found ordinarily in the unmodied host food. FDA provides extensive guidance
in recommending safety issues to be addressed, but once again leaves compli-
ance with the food producer. There is no requirement for notication or prior
approval; once again, the agency envisages a more limited consultative and
policing role.
FDA has also shown reluctance to impose strict labeling requirements for
genetically engineered foods. The agency asserts its broad power under x 403(i)
combined with xx 403(a) & 201(n) to require disclosure not only of a food's
common or usual name, but also of any material dierence from foods tradi-
tionally described by that name and of any material safety or usage issue. Yet
FDA does not require disclosure that a food is genetically engineered, nor that
proteins derived from other (donor) foods are present unless the donor food
commonly produces allergic reactions. Even then, no disclosure is required if
there is sucient information showing that the (major) allergenic components
of the donor food are known and are not present in the proteins introduced into
the host food.'9 The agency takes the view that genetic engineering techniques
are merely extensions of traditional breeding methods and that the resulting
foods do not dier from other foods in any meaningful or uniform way.
Evaluation of FDA's regulatory strategy
While FDA's general approach is scientically sound, and its restrained ap-
proach undoubtedly within its statutory discretion, the agency appears to have
erred on the side of under-
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The agency's decision to incorporate genetically engineered food into its ex-
isting regulatory structure seems wise. The very broad discretion and enforce-
ment powers granted in the FDCA would permit virtually whatever regulation
the agency wished to impose. By asserting a broad interpretation of the in-
tended use test of x 201(s), together with a strict view of GRAS, FDA could
impose a premarket approval regime for all genetically engineered foods. Sim-
ilarly, its discretion on what disclosures are material for labeling is in practice
unreviewable. By eschewing a request for new statutory powers, FDA avoided
forcing on Congress a sensitive and emotive issue on which the general public
has not yet had time to frame a considered opinion. Any Congressional action
could scarcely have given FDA more eective powers; the only change likely to
arise from new legislation would be an attempt to impose a stricter regulatory
duty on the agency. If at all eective, the result would have been to lock in a
rigid and inexible regulatory regime.
Since FDA is operating within the realm of discretion, it should consider the
following changes to its regulatory strategy:
(1) A more subtly tailored licensing and notication regime.
USDA provides a regulatory model which is readily applicable to genetically
engineered foods. While it is impractical and unnecessary to regulate each in-
dividual food item, the number of new plants is much more limited and could
readily be regulated by a combined licensing and notication scheme. Genet-
ically engineered modications would in general require premarket approval.
Where FDA was satised that a commonly used technique was safe (such as
using the k~~d gene as an antibiotic resistance marker) it could be designated
as approved and exempted from licensing. Even greater exibility could be
achieved by designating standards rather than individual genes (e.g. to ensure
stable integration of the new genetic material in the host); this would approach
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should insist on notication and should maintain a database of foods containing
genetically engineered components. The agency should also consider imposing
monitoring requirements for adverse reactions associated with the new products.
It is true, as FDA asserts, that genetic engineering is an extension of tradi-
tional breeding and other techniques, and that any change to a food crop may
produce unintended eects. However, this does not justify turning a blind regu-
latory eye to possible adverse eects from one of the most powerful technologies
known to mankind, and one that could rapidly and profoundly transform the
human diet. Monitoring suspected allergic and other adverse reactions could
give early warning of unforeseen problems and would allow FDA to forestall
some future crisis that might jeopardize public acceptance of all genetically
engineered foods.
Given the extensive consultation envisaged by FDA, and conducted with the
pioneering products currently approaching market, this new regime would not
greatly increase the industry's regulatory burden. Indeed, recent developments
suggest that the industry might prefer tighter regulation to help it overcome
public hesitancy about the new technology. The perception, of unbridled dereg-
ulation is deeply damaging to this emerging sector, as the FDA Commissioner
franldy admitted? Moreover, Calgene has requested that FDA regulate the
ka~ gene and its enzyme product as food additives in order to help correct
misunderstanding by the public as to the scope and rigor of FDA's review of
new [genetically engineered] food products[,]...~ underscore the adequacy of the
FDA policy and provide condence to the public. ... 21 The potential for adverse
public reaction was underscored when prominent restauranteurs announced a
boycott of genetically engineered foods, and when Campbell Soup Co. canceled
plans to use the Flavr Savr tomato, apparently in response to public pressure.
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FDA has not persuasively justied its refusal to treat the fact that a food
is genetically engineered, and the species of origin of the genetically introduced
protein as material facts requiring disclosure. Consumers with religious, moral
or aesthetic scruples are entitled to decide for themselves whether the essen-
tial nature of a food has been altered, whatever FDA concludes. Consumers
who are allergic to some foods are entitled to fair warning that an apparently
familiar food may contain new ingredients, so that they may take appropriate
precautions. Fortunately, FDA appears to be rethinking its position in the light
of comments responding to its 1992 Statement of Policy.~
Calgene's marketing plans illustrate the feasibility of labeling genetically en-
gineered fruits and vegetables, since the company intends to mark each tomato
with a circular label. The proposed wording, however, illustrates the need for
regulation. The label will identify the product as Macgregor's Tomatoes. Grown
From Flavr Savr Seeds. Point of sale information will disclose use of the lat-
est developments in genetic engineering, tomato plant breeding, and farming
as well as insertion of a gene which makes a naturally occurring protein [that]
makes Flavr Savr seeds resistant to kanamycin contained in our test medium. 23
Taken as whole, this seems fair. Without the point of sale information, however,
the label's folksy name would be misleading. Without regulatory deterrence,
unscrupulous producers (or retailers) might be tempted to omit disclosing the
use of genetic engineering, especially if such products encounter consumer resis-
tance.
(3) Imposing Current Good Manufacturing Practice requirements
FDA has asserted the power under x 70 1(a) to impose CGMP requirements
for food manufacturing, processing and storage and has used its authority to
impose recordkeeping duties~ This section provides an alternative source of au-
thority for requiring producers and retailers to keep
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corporated into processed foods. This authority could also be used to impose
technical standards for insertion of genetic material (e.g. stable insertion of
well-characterized constructs) even if FDA wishes to avoid treating these com-
ponents as additives.
~Qn~Qn
In framing a regulatory response to new technologies that aect the food
supply, FDA must deal not only with legal and scientic issues, but also with
popular perceptions. The public holds the agency in high regard and trusts
it to ensure the safety and accurate identication of foods. This mandate the
agency must not only discharge, but also be seen to discharge. FDA's present
approach to genetically engineered plants is scientically and legally defensible,
but takes too little account of public perceptions. In seeking to encourage the
food biotechnology industry, FDA is harming it through under-regulation.
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